Today, there are no approved therapies to treat Long COVID or its symptoms. This has left millions of patients suffering and waiting for answers.

A new program is working to change that. Researching COVID to Enhance Recovery–Treating Long COVID (RECOVER-TLC) is an FNIH initiative led by the National Institute of Allergy and Infectious Diseases (NIAID). Our goal is to unite the scientific and patient communities in finding new approaches to address Long COVID.

RECOVER-TLC will apply lessons learned from an earlier program, RECOVER, launched in 2021 by the National Institutes of Health (NIH).

As an important first step, we are inviting the community to help identify promising therapeutic approaches. This could include proposed drugs, devices, or other therapeutic agents targeted at alleviating symptoms associated with Long COVID. We encourage all individuals – patients, caregivers, scientists, etc. – to share their ideas.

Submit a Therapeutic
for Consideration
 

Learn more about our process for reviewing therapeutics submissions.

Goals

  • Identify safe and effective interventions for treating Long COVID and bring these to healthcare providers for their patients as rapidly as possible

  • Leverage and expand on findings from previous research efforts, including ongoing RECOVER cohorts and clinical trials

  • Launch clinical trials that include transparent engagement with scientific leaders and people with lived experience

  • Encourage swift dissemination of data across the scientific community and the public

Staying Connected

We are committed to engaging members of the Long COVID community. We use newsletters and webinars, alternating monthly, to keep everyone updated. This includes patients, advocates, academia, researchers, scientists, and clinical communities.


RECOVER-TLC Scientific Workshop

More than 1,400 people gathered for the first RECOVER-TLC Workshop in Bethesda, Md., Sept. 23-25, 2024. Videos of each session are available below.

Click the playlist button at the top right
of the video viewer for additional panels

Download a summary
 
This in-depth document will download as a PDF

RECOVER-TLC Background

RECOVER-TLC will build on the work of the RECOVER program, which is led by three NIH Institutes: The National Heart, Lung, and Blood Institute (NHLBI); NIAID; and the National Institute of Neurological Disorders and Stroke (NINDS).

RECOVER has engaged more than 30,000 people in ongoing studies and clinical trials. This has created a research engine of unprecedented scale and scope, including one of the largest and most diverse Long COVID cohorts in the world. This work has advanced our understanding and provided valuable insights into designing and conducting clinical trials to address patient-centered endpoints. Data from ongoing RECOVER trials and studies will inform RECOVER-TLC efforts.

Partners

Public-Sector Partners
  • National Center for Advancing Translational Sciences’
  • National Heart, Lung, and Blood Institute
  • National Institute for Neurologic Diseases and Stroke
  • National Institute of Allergy and Infectious Disease
Contact
Lizzie Geerling, PhD

Associate Project Manager, Translational Science

[email protected]
Stacey Adam, PhD

Vice President, Science Partnerships Translational Science

[email protected]

Donate

Donate to the FNIH today to support medical research that saves lives

Partner With Us

Work with the FNIH to accelerate medical breakthroughs for patients